Antigen-presenting cell and T lymphocyte interaction (APC-T cell axis)

The interaction between Antigen-Presenting Cells (APCs) and T lymphocytes is the fundamental mechanism of adaptive immunity, involving the presentation of peptide-MHC complexes to T-cell receptors (TCRs). This cellular interface, often referred to as the immune synapse, is governed by a complex balance of co-stimulatory signals (such as CD28-CD80/86) and co-inhibitory checkpoints (such as PD-1/PD-L1 and CTLA-4) (StatPearls, 2023). In many diseases, this axis is dysregulated; for instance, tumors often exploit inhibitory pathways to induce T-cell exhaustion and evade immune surveillance (NIH, 2024). Conversely, in autoimmune disorders, the loss of self-tolerance leads to inappropriate T-cell activation against host tissues. Therapeutic intervention at this level includes checkpoint inhibitors to bolster anti-tumor responses and immunosuppressants to dampen pathological inflammation (PubMed, 2022). Because this entry describes a multi-cellular system rather than a discrete molecular entity, it serves as a framework for various specific drug targets rather than a single druggable receptor.

Other names

Immune synapseAPC-T cell interactionAdaptive immune system componentsAntigen presentation pathway

Drugs targeting this interaction typically modulate the immune synapse by either blocking inhibitory checkpoints (e.g., PD-1, CTLA-4) to enhance T-cell effector function against tumors, or by inhibiting co-stimulatory signals (e.g., CD80/86) and TCR signaling to suppress pathological immune responses in autoimmunity and organ transplantation.